Follow
Steven Xu
Title
Cited by
Cited by
Year
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3†…
MV Mateos, H Nahi, W Legiec, S Grosicki, V Vorobyev, I Spicka, ...
The lancet haematology 7 (5), e370-e380, 2020
2032020
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
T Casneuf, XS Xu, HC Adams III, AE Axel, C Chiu, I Khan, T Ahmadi, ...
Blood advances 1 (23), 2105-2114, 2017
1842017
Percutaneous absorption of trihalomethanes, haloacetic acids, and haloketones
X Xu, TM Mariano, JD Laskin, CP Weisel
Toxicology and Applied Pharmacology 184 (1), 19-26, 2002
1752002
Simultaneous and sensitive measurement of anabasine, nicotine, and nicotine metabolites in human urine by liquid chromatography–tandem mass spectrometry
X Xu, MM Iba, CP Weisel
Clinical Chemistry 50 (12), 2323-2330, 2004
1292004
Selective detection of monohydroxy metabolites of polycyclic aromatic hydrocarbons in urine using liquid chromatography/triple quadrupole tandem mass spectrometry
X Xu, J Zhang, L Zhang, W Liu, CP Weisel
Rapid Communications in Mass Spectrometry 18 (19), 2299-2308, 2004
1272004
Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency
RJ Auchus, EO Buschur, AY Chang, GD Hammer, C Ramm, D Madrigal, ...
The Journal of Clinical Endocrinology & Metabolism 99 (8), 2763-2770, 2014
842014
Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients
XS Xu, CJ Ryan, K Stuyckens, MR Smith, F Saad, TW Griffin, YC Park, ...
Clinical Cancer Research 21 (14), 3170-3177, 2015
722015
Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment
PL Clemens, X Yan, HM Lokhorst, S Lonial, N Losic, I Khan, R Jansson, ...
Clinical pharmacokinetics 56, 915-924, 2017
702017
Clinical implications of complex pharmacokinetics for daratumumab dose regimen in patients with relapsed/refractory multiple myeloma
XS Xu, X Yan, T Puchalski, S Lonial, HM Lokhorst, PM Voorhees, ...
Clinical Pharmacology & Therapeutics 101 (6), 721-724, 2017
662017
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes
XS Xu, K Moore, P Burton, K Stuyckens, W Mueck, S Rossenu, ...
British journal of clinical pharmacology 74 (1), 86-97, 2012
602012
Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact
XS Xu, M Yuan, MO Karlsson, A Dunne, P Nandy, A Vermeulen
The AAPS journal 14, 927-936, 2012
592012
A Bayesian population PBPK model for multiroute chloroform exposure
Y Yang, X Xu, PG Georgopoulos
Journal of exposure science & environmental epidemiology 20 (4), 326-341, 2010
522010
Stratification of population in NHANES 2009–2014 based on exposure pattern of lead, cadmium, mercury, and arsenic and their association with cardiovascular, renal and†…
X Yao, XS Xu, Y Yang, Z Zhu, Z Zhu, F Tao, M Yuan
Environment international 149, 106410, 2021
502021
Population pharmacokinetic analysis of abiraterone in chemotherapy-naÔve and docetaxel-treated patients with metastatic castration-resistant prostate cancer
K Stuyckens, F Saad, XS Xu, CJ Ryan, MR Smith, TW Griffin, MK Yu, ...
Clinical pharmacokinetics 53, 1149-1160, 2014
492014
Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain
XS Xu, JW Smit, R Lin, K Stuyckens, R Terlinden, P Nandy
Clinical pharmacokinetics 49, 671-682, 2010
432010
Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models
XS Xu, A Dunne, H Kimko, P Nandy, A Vermeulen
Journal of pharmacokinetics and pharmacodynamics 38, 423-432, 2011
372011
Influence of disease and patient characteristics on daratumumab exposure and clinical outcomes in relapsed or refractory multiple myeloma
X Yan, PL Clemens, T Puchalski, S Lonial, H Lokhorst, PM Voorhees, ...
Clinical pharmacokinetics 57, 529-538, 2018
282018
Pharmacokinetics and exposure–response analyses of daratumumab in combination therapy regimens for patients with multiple myeloma
XS Xu, MA Dimopoulos, P Sonneveld, PJ Ho, A Belch, M Leiba, M Capra, ...
Advances in therapy 35, 1859-1872, 2018
262018
Pharmacokinetic and pharmacodynamic modeling of opioid-induced gastrointestinal side effects in patients receiving tapentadol IR and oxycodone IR
XS Xu, M Etropolski, D Upmalis, A Okamoto, R Lin, P Nandy
Pharmaceutical research 29, 2555-2564, 2012
262012
Target-mediated drug disposition of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitors and immunomodulatory†…
X Yan, PL Clemens, T Puchalski, S Lonial, HM Lokhorst, RZ Orlowski, ...
Blood, The Journal of the American Society of Hematology 126 (23), 4222-4222, 2015
222015
The system can't perform the operation now. Try again later.
Articles 1–20